Vaxart, Inc. (NASDAQ:VXRT – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Vaxart in a research report issued on Monday, June 6th. Cantor Fitzgerald analyst C. Duncan forecasts that the biotechnology company will earn ($1.29) per share for the year.
Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Vaxart from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. B. Riley dropped their price target on Vaxart from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Thursday, May 19th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Vaxart presently has a consensus rating of “Buy” and an average price target of $11.50.
Vaxart (NASDAQ:VXRT – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $0.09 million during the quarter. Vaxart had a negative return on equity of 41.95% and a negative net margin of 16,892.57%.
Several institutional investors have recently bought and sold shares of VXRT. Morgan Stanley increased its position in shares of Vaxart by 203.5% in the second quarter. Morgan Stanley now owns 265,935 shares of the biotechnology company’s stock valued at $1,992,000 after buying an additional 178,320 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Vaxart by 58.0% in the second quarter. Royal Bank of Canada now owns 23,380 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 8,578 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Vaxart by 154.9% in the second quarter. Invesco Ltd. now owns 54,892 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 33,360 shares during the last quarter. Barclays PLC boosted its stake in shares of Vaxart by 106.9% in the third quarter. Barclays PLC now owns 51,015 shares of the biotechnology company’s stock worth $407,000 after acquiring an additional 26,362 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Vaxart by 16.5% in the third quarter. Alliancebernstein L.P. now owns 106,400 shares of the biotechnology company’s stock worth $846,000 after acquiring an additional 15,100 shares during the last quarter. Institutional investors and hedge funds own 45.91% of the company’s stock.
Vaxart Company Profile (Get Rating)
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- Is It Too Late For Energy Stocks?
- Chargepoint’s Stock Could Benefit from High Energy Prices
- MarketBeat Podcast: Get Your Mindset Right To Invest In The Current Market
- It’s Time To Get Interested In Ethereum Again
- Stratasys Stock Forming a Tradeable Bottom
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.